Emphasizing statin safety in the hospitalized patient: a review

Alicia Leung1, Eric W Schaefer, Michael W Tempelhof

  • 1Division of Hospital Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Insights

This review highlights the safe initiation of statin therapy in hospitalized patients with cardiovascular conditions, diabetes, or kidney disease. It emphasizes understanding statin metabolism and drug interactions to prevent adverse effects in acute care settings.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hospital Medicine

Background:

  • Cardiovascular disease remains a leading cause of morbidity and mortality.
  • Statin therapy is a cornerstone in managing cardiovascular disease.
  • Hospitalized patients often have complex medical conditions and polypharmacy, increasing risks.

Purpose of the Study:

  • To review the safety and efficacy of initiating statin therapy in hospitalized patients.
  • To identify patient populations who benefit from statin initiation during hospitalization.
  • To inform hospital physicians about statin metabolism and drug interactions to mitigate adverse events.

Main Methods:

  • Literature review of available data on statin therapy in hospitalized patients.
  • Examination of statin metabolism and pharmacokinetic profiles.
  • Analysis of drug-drug interactions relevant to the hospital environment.

Main Results:

  • Statin initiation is supported in acute coronary syndromes, established cardiovascular disease, and high-risk diabetes/chronic kidney disease patients.
  • Consideration for statin use in solid-organ transplant survivors and HIV patients on protease inhibitors is noted.
  • Safety concerns, particularly drug-drug interactions, are critical in the acute care setting.

Conclusions:

  • Initiating statin therapy during hospitalization is beneficial for specific patient groups.
  • Hospital physicians must be aware of statin metabolism and potential drug interactions.
  • Minimizing adverse statin effects is crucial for safe and effective patient care in hospitals.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...